Durvalumab after initial treatment for limited-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (stage I–III) that hasn't spread far.
- You haven't had prior chemotherapy or radiation for this cancer.
- You have a performance status of 0 or 1 (able to do daily activities with little or no help).
- You are at least 18 years old and expected to live 12 weeks or more.
- No active autoimmune diseases, organ transplant, or serious infections like hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
Hear when a new Small Cell Lung Cancer Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.